Abbott seeks appeal on royalties to UK's Cambridge
Tuesday, 15 February, 2005
Abbott Laboratories is seeking to appeal a British court ruling that granted Cambridge Antibody Technology a greater percentage of royalties on Abbott's arthritis drug Humira.
In December, UK Judge Hugh Laddie said Abbott should pay Cambridge a royalty of just over 5 per cent on sales of Humira, compared with the royalty of 2 per cent of net sales it has been paying.
The application will be considered by one Court of Appeal judge, Cambridge said in a statement. If the application is unsuccessful, Abbott will be entitled to request a hearing.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
